[1] Rajkumar SV, Larson D, Kyle RA.Diagnosis of smoldering multiple myeloma[J]. N Engl J Med,2011,365(5):474-475.
[2] Kastritis E, Terpos E, Moulopoulos L, et al.Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease[J]. Leukemia,2013,27(4):947-953.
[3] Waxman AJ, Mick R, Garfall AL, et al.Modeling the risk of progression in smoldering multiple myeloma[J]. J Clin Oncol,2014,32(5s):A8607.
[4] Larsen JT, Kumar SK, Dispenzieri A, et al.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma[J]. Leukemia,2013,27(4):941-946.
[5] Hillengass J, Fechtner K, Weber MA, et al.Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma[J]. J Clin Oncol,2010,28(9):1606-1610.
[6] Kastritis E, Moulopoulos LA, Terpos E, et al.The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma[J]. Leukemia,2014,28(12):2402-2403.
[7] Palumbo A, Avet-Loiseau H, Oliva S, et al.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group[J]. J Clin Oncol,2015,33(26):2863-2869.
[8] Palumbo A, Bringhen S, Mateos MV, et al.Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report[J]. Blood,2015,125(13):2068-2074.
[9] Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2017,28(suppl_4):iv52-iv61.
[10] Palumbo A, Hajek R, Delforge M, et al.Continuous lenalidomide treatment for newly diagnosed multiple myeloma[J]. N Engl J Med,2012,366(19):1759-1769.
[11] Attal M, Palumbo A, Holstein SA, et al.Lenalidomide maintenance after high-dose melphalan and autologous stem-cell transplantation in multiple myeloma: a meta-analysis of overall survival[J]. J Clin Oncol,2016,34(Suppl):8001.
[12] Laubach J, Garderet L, Mahindra A, et al.Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group[J]. Leukemia,2016, 30(5):1005-1017.
[13] Stewart AK, Rajkumar SV, Dimopoulos MA, et al.Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma[J]. N Engl J Med,2015,372(2):142-152.
[14] Dimopoulos MA, Moreau P, Palumbo A, et al.Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study[J]. Lancet Oncol,2016,17(1):27-38.
[15] Lonial S, Dimopoulos M, Palumbo A, et al.Elotuzumab therapy for relapsed or refractory multiple myeloma[J]. N Engl J Med,2015,373(7):621-631.
[16] Moreau P, Masszi T, Grzasko N, et al.Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med,2016,374(17):1621-1634.
[17] San-Miguel JF, Hungria VT, Yoon SS, et al.Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial[J]. Lancet Oncol,2014,15(11):1195-1206.
[18] San Miguel J, Weisel K, Moreau P, et al.Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial[J]. Lancet Oncol,2013,14(11):1055-1066.
[19] Usmani SZ, Weiss BM, Plesner T, et al.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma[J]. Blood,2016,128(1):37-44.
[20] Palumbo A, Chanan-Khan A, Weisel K, et al.Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma[J]. N Engl J Med,2016,375(8):754-766.
[21] Dimopoulos MA, Oriol A, Nahi H, et al.Daratumumab, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med,2016,375(14):1319-1331.
